Falsified Medical Product Alert N°7/2025

IBRANCE (palbociclib) capsules: falsified product alert

WHO issued this alert on falsified IBRANCE, a breast cancer medicine, reported to WHO in November 2025. Four lot numbers are not valid for genuine IBRANCE and five genuine lot numbers are flagged as suspicious when combined with other indicators. The products were offered to consumers online and also found in pharmacies. Indicators include capsules marked PBC 125 in black ink or unmarked capsules.¹

Health risk as statedWHO said these falsified medicines did not contain any active pharmaceutical ingredient and should be considered unsafe.

Issued: 15 December 2025
Issued by: World Health Organization
Name stated on packaging: Falsified labels state Manufactured by Pfizer, PO Box 29387, Mission, KS 66201. WHO lists this as a falsification indicator, not a genuine detail.
Genuine manufacturer's statement: WHO said the genuine manufacturer confirmed the listed products are falsified, found no active pharmaceutical ingredient in samples and identified visual packaging discrepancies.
Countries where detected: Côte d'Ivoire, Egypt, Lebanon, Libya, Türkiye

Batches named in the alert

FS5173 (not valid), GS4328 (not valid), LV1850 (not valid), TS2190 (not valid), GK2981 (suspicious), GR6491 (suspicious), GT5817 (suspicious), HJ8710 (suspicious), HJ8715 (suspicious)

Advice as stated

Do not use the listed products. Obtain medicines only from authorised or licensed suppliers. Report adverse events, lack of effect or suspected falsification to the national regulatory authority or pharmacovigilance centre.

Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.

Sources

World Health Organization, Medical Product Alert N°7/2025: Falsified IBRANCE (palbociclib) (15 December 2025)